Every cancer specimen is genetically unique, yet all share common traits like uncontrolled division and co-opting normal cell survival mechanisms. The key to treatment is finding pathways that are different enough from normal cells to target and exploit.

Dr. Levin reframes cancer as a cognitive problem where the bioelectric "glue" binding cells into a collective fails. Cells lose their large-scale purpose and revert to an ancient, single-cell state. Restoring this electrical communication can normalize tumors without killing the cells, presenting a non-destructive therapeutic approach.

Immuno-oncology is not a one-time fix because cancer cells are described as "smart" adversaries that quickly adapt and develop resistance. The future of treatment lies in staying a step ahead, constantly switching therapeutic mechanisms to outmaneuver the cancer's ability to learn.

An individual tumor can have hundreds of unique mutations, making it impossible to predict treatment response from a single genetic marker. This molecular chaos necessitates functional tests that measure a drug's actual effect on the patient's cells to determine the best therapy.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

The same cancer-driving mutation behaves differently depending on the cell's internal "wiring." For example, a drug targeting a mutation works in melanoma but induces resistance in colorectal cancer due to a bypass pathway. This cellular context is why genetic data alone is insufficient.

Many blood cancers are better understood as "regulatory problems" driven by epigenetic failures—the systems controlling which genes are turned on or off. This shifts the therapeutic focus from targeting DNA mutations to developing drugs, like IDH inhibitors, that correct these underlying control mechanisms.

Up to a third of CDK inhibitor resistance cases show no known DNA mutations. Dr. Wander suggests epigenetic factors, like DNA methylation altering chromatin architecture, are responsible. These "dark matter" events turn genes on or off without changing the DNA code, requiring new blood-based profiling technologies to detect and understand resistance.

A tumor can be viewed as an evolving system within the body's environment. It progresses from stage to stage by "ratcheting up" its functional information—its ability to survive and grow. This evolutionary framework could inspire novel cancer treatments.